收费全文 | 302912篇 |
免费 | 18577篇 |
国内免费 | 8027篇 |
耳鼻咽喉 | 3451篇 |
儿科学 | 10133篇 |
妇产科学 | 4025篇 |
基础医学 | 20152篇 |
口腔科学 | 8565篇 |
临床医学 | 34547篇 |
内科学 | 49293篇 |
皮肤病学 | 4550篇 |
神经病学 | 16223篇 |
特种医学 | 14164篇 |
外国民族医学 | 44篇 |
外科学 | 41414篇 |
综合类 | 33923篇 |
现状与发展 | 32篇 |
一般理论 | 4篇 |
预防医学 | 20900篇 |
眼科学 | 5878篇 |
药学 | 32006篇 |
234篇 | |
中国医学 | 13137篇 |
肿瘤学 | 16841篇 |
2024年 | 506篇 |
2023年 | 3166篇 |
2022年 | 6520篇 |
2021年 | 13365篇 |
2020年 | 8731篇 |
2019年 | 13691篇 |
2018年 | 8239篇 |
2017年 | 7751篇 |
2016年 | 9973篇 |
2015年 | 12586篇 |
2014年 | 23294篇 |
2013年 | 23247篇 |
2012年 | 24305篇 |
2011年 | 21450篇 |
2010年 | 19342篇 |
2009年 | 18245篇 |
2008年 | 16314篇 |
2007年 | 16603篇 |
2006年 | 14172篇 |
2005年 | 9972篇 |
2004年 | 5973篇 |
2003年 | 5207篇 |
2002年 | 4265篇 |
2001年 | 3402篇 |
2000年 | 3016篇 |
1999年 | 2080篇 |
1998年 | 2373篇 |
1997年 | 2176篇 |
1996年 | 1786篇 |
1995年 | 1762篇 |
1994年 | 1675篇 |
1993年 | 1356篇 |
1992年 | 1478篇 |
1991年 | 1320篇 |
1990年 | 1286篇 |
1989年 | 1260篇 |
1988年 | 1158篇 |
1987年 | 1041篇 |
1986年 | 870篇 |
1985年 | 1823篇 |
1984年 | 1932篇 |
1983年 | 1393篇 |
1982年 | 1513篇 |
1981年 | 1458篇 |
1980年 | 1256篇 |
1979年 | 1094篇 |
1978年 | 818篇 |
1977年 | 812篇 |
1976年 | 710篇 |
1974年 | 470篇 |
Background
The purpose of the study was to evaluate the association between fetal echocardiographic measurements and the need for intervention (primary coarctation repair, staged coarctation repair, or catheter intervention) in prenatally diagnosed coarctation of the aorta.Methods
A single-centre retrospective cohort study (2005-2015) of 107 fetuses diagnosed with suspected coarctation of the aorta in the setting of an apex-forming left ventricle and antegrade flow across the mitral and aortic valves.Results
Median gestational age at diagnosis was 32 weeks (interquartile range, 23-35 weeks). Fifty-six (52%) did not require any neonatal intervention, 51 patients (48%) underwent a biventricular repair. In univariable analysis, an increase in ascending aorta (AAo) peak Doppler flow velocity (odds ratio [OR], 1.40 [95% confidence interval [CI], 1.05-1.91] per 20 cm/s; P = 0.03) was associated with intervention. No intervention was associated with larger isthmus size (OR, 0.23; P < 0.001), transverse arch diameter (OR, 0.23; P < 0.001), and aortic (OR, 0.72; P = 0.02), mitral (OR, 0.58; P = 0.001), and AAo (OR, 0.53; P < 0.001) z-scores. In multivariable analysis, higher peak AAo Doppler (OR, 2.51 [95% CI, 1.54-4.58] per 20 cm/s; P = 0.001) and younger gestational age at diagnosis (OR, 0.81 [95% CI, 0.70-0.93] per week; P = 0.005) were associated with intervention, whereas a higher AAo z-score (OR, 0.65 [95% CI, 0.43-0.94] per z; P = 0.029) and transverse arch dimension (OR, 0.44 [95% CI, 0.18-0.97]; P = 0.05) decreased the risk of intervention.Conclusions
In prenatally suspected coarctation, the variables associated with intervention comprised smaller AAo and transverse arch size, earlier gestational age at diagnosis, and the additional finding of a higher peak AAo Doppler. 相似文献Methods: A systematic literature search was performed to identify relevant randomized controlled trials (RCTs). Key outcomes of interest were clinical response (CD activity index [CDAI] reduction of 100 points; CDAI-100) and remission (CDAI score under 150 points; CDAI < 150). A treatment sequence Bayesian NMA was conducted to account for the re-randomization of patients based on different clinical definitions, the lack of similarity of the common comparator for each trial and the full treatment pathway from the induction phase onwards.
Results: Thirteen RCTs were identified. Ustekinumab 90?mg q8w was associated with statistically significant improvement in clinical response relative to placebo and vedolizumab 300?mg. For clinical remission, ustekinumab 90?mg q8w was associated with statistically significant improvement relative to placebo and vedolizumab 300?mg q8w. Findings from sub-population analyses had similar results but were not statistically significant.
Conclusions: The NMA suggest that ustekinumab is associated with the highest likelihood of reaching response or remission at 1?year compared with placebo, adalimumab and vedolizumab. Results should be interpreted with caution because this is a novel methodology; however, the treatment sequence analysis may be the most methodologically sound analysis to derive estimates of comparative efficacy in CD in the absence of head-to-head evidence. 相似文献